Brawn biotech Limited has officially communicated to BSE Limited that it does not qualify as a Large Corporate under the Securities and Exchange Board of India's regulatory framework. The declaration was submitted on April 13, 2026, by Company Secretary and Compliance Officer Priyanka Sharma.

Regulatory Compliance Declaration

The company's declaration references two key SEBI circulars that govern fund raising by Large Corporates through debt securities. These include SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, and SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023. Under these regulations, companies meeting specific criteria must comply with enhanced disclosure requirements and borrowing frameworks.

Company Financial Position

The formal disclosure reveals Brawn Biotech Limited's current financial standing regarding borrowings and credit ratings:

Large Corporate Framework Criteria

The SEBI Large Corporate framework establishes specific thresholds and criteria that determine whether a company falls under enhanced regulatory oversight for debt securities. Companies that qualify as Large Corporates face additional compliance requirements, including mandatory borrowing through debt securities for incremental funding needs above specified limits.

Corporate Information

Brawn Biotech Limited operates with CIN L74899DL1985PLC022468 and maintains its registered office at C-64, Lajpat Nagar-1, First Floor, New Delhi-110024. The company's manufacturing facility is located at Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram, Haryana. The declaration was digitally signed and submitted with the company's official seal, ensuring proper authentication of the regulatory communication.

Brawn biotech Limited has submitted its quarterly compliance certificate to BSE Limited, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The certificate covers the quarter ended March 31, 2026, and was filed on April 7, 2026, by Company Secretary and Compliance Officer Priyanka Sharma.

Regulatory Compliance Details

The submission relates to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, which mandates quarterly compliance reporting for dematerialisation processes. The certificate was prepared by RCMC Share Registry Private Limited, serving as the company's registrar and share transfer agent.

Dematerialisation Process Confirmation

RCMC Share Registry Private Limited confirmed that all securities received from depository participants for dematerialisation during the quarter ended March 31, 2026 were properly processed. The registrar verified that securities comprised in the certificates have been listed on stock exchanges where the company's earlier issued securities are already listed.

The compliance certificate specifically confirms several key operational aspects:

• Securities received for dematerialisation were confirmed to depositories
• Security certificates were mutilated and cancelled after due verification
• Depository names were substituted in the register of members as registered owners
• All processes were completed within the prescribed 15-day timeframe

Company Information

Brawn Biotech Limited operates with its registered office located at C-64, Lajpat Nagar-1, First Floor, New Delhi-110024. The company's manufacturing facility is situated at Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram, Haryana. The company's shares are listed on BSE with scrip code 530207 and scrip ID BRAWN.

Regulatory Framework

The SEBI (Depositories and Participants) Regulations, 2018 require companies to maintain proper records and processes for dematerialisation of securities. Regulation 74(5) specifically mandates quarterly certification to ensure transparency and compliance in the depository system. This regulatory framework helps maintain investor confidence and ensures proper handling of securities in electronic form.